C5a-C5aR1 Axis Blockade in Patients With Severe COVID-19: Contrasting Results of PANAMO and FORCE-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

C5a-C5aR1 Axis Blockade in Patients With Severe COVID-19: Contrasting Results of PANAMO and FORCE

Published:2023-04-13 Issue:5 Volume:51 Page:e129-e130
ISSN:0090-3493
Container-title:Critical Care Medicine
language:en
Short-container-title:

Author:

Carvelli Julien¹²³,Vivier Eric²³⁴⁵

Affiliation:

1. Assistance Publique des Hôpitaux de Marseille, Hôpital de la Timone, Réanimation des Urgences, Marseille, France.

2. Aix Marseille Univ, Marseille, France.

3. Assistance Publique des Hôpitaux de Marseille, Hôpital de la Timone, Immunology, Marseille Immunopole, Marseille, France.

4. Aix Marseille Univ, CNRS, INSERM, CIML, Marseille, France.

5. Innate Pharma, Marseille, France.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Critical Care and Intensive Care Medicine

Reference5 articles.

1. Association of COVID-19 inflammation with activation of the C5a–C5aR1 axis.;Carvelli;Nature,2020

2. Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): A multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.;Vlaar;Lancet Respir Med,2022

3. Avdoralimab (Anti-C5aR1 mAb) Versus Placebo in Patients With Severe COVID-19: Results From a Randomized Controlled Trial (FOR COVID Elimination [FORCE]);Carvelli;Crit Care Med,2022

4. SARS-CoV-2 variants, spike mutations and immune escape.;Harvey;Nat Rev Microbiol,2021

5. Functional roles for C5a receptors in sepsis.;Rittirsch;Nat Med,2008

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Complement in human disease: approved and up-and-coming therapeutics;The Lancet;2024-01

2. C5a-C5aR1 Axis Blockade in Patients With Severe COVID-19: Differences Between PANAMO and FORCE Study;Critical Care Medicine;2023-10-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3